Superior Outcomes Documented with Cordis Eluting Stent in Diabetics
A study published in the Journal of the American College of Cardiology validated superior outcomes with use of the Cypher drug-eluting stent manufactured by Cordis in patients with diabetes. The study compared use of this stent to the Taxus stent from Boston Scientific.
The study was completed over a two year period, between 2005 and 2006, in a number of different facilities in South Korea. Over 400 patients with diabetes were recruited to participate in the randomized trial. Patients were evenly distributed between the two study arms.
Data collected from the trial indicates that the Cypher stent had a lower rate of reblockage in the area treated than the Taxus. Patients were also less likely to experience significant adverse events or require additional interventional procedures after nine months of follow up.
Notably, at this point in time, the Cypher has not received FDA approval to treat those patients with diabetes.